{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:46:06Z","timestamp":1794635166081,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-020-0053-3","type":"journal-article","created":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T16:56:37Z","timestamp":1588006597000},"page":"493-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":379,"title":["Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma"],"prefix":"10.1038","volume":"1","author":[{"given":"Oksana","family":"Zavidij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1113-3135","authenticated-orcid":false,"given":"Nicholas J.","family":"Haradhvala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-5978","authenticated-orcid":false,"given":"Tarek H.","family":"Mouhieddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romanos","family":"Sklavenitis-Pistofidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-4356","authenticated-orcid":false,"given":"Songjie","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mairead","family":"Reidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7100-463X","authenticated-orcid":false,"given":"Mahshid","family":"Rahmat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdallah","family":"Flaifel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ferland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nang K.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2356-4274","authenticated-orcid":false,"given":"Michael P.","family":"Agius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bustoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Capelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Berrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7945-9292","authenticated-orcid":false,"given":"Chia-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng Xiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosef E.","family":"Maruvka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Guerriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-4444","authenticated-orcid":false,"given":"Eliezer M.","family":"Van Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"McCarroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamil","family":"Azzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":false,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":false,"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"key":"53_CR1","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","volume":"111","author":"RA Kyle","year":"2008","unstructured":"Kyle, R. A. & Rajkumar, S. V. Multiple myeloma. Blood 111, 2962\u20132972 (2008).","journal-title":"Blood"},{"key":"53_CR2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/asheducation-2013.1.478","volume":"2013","author":"O Landgren","year":"2013","unstructured":"Landgren, O. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies. Hematology Am. Soc. Hematol. Educ. Program 2013, 478\u2013487 (2013).","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"53_CR3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/ajh.21913","volume":"86","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar, S. V. Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 86, 57\u201365 (2011).","journal-title":"Am. J. Hematol."},{"key":"53_CR4","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"RA Kyle","year":"2010","unstructured":"Kyle, R. A. et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24, 1121\u20131127 (2010).","journal-title":"Leukemia"},{"key":"53_CR5","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar, S. V. et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106, 812\u2013817 (2005).","journal-title":"Blood"},{"key":"53_CR6","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","volume":"27","author":"SV Rajkumar","year":"2013","unstructured":"Rajkumar, S. V. et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27, 1738\u20131744 (2013).","journal-title":"Leukemia"},{"key":"53_CR7","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","volume":"108","author":"I Hanamura","year":"2006","unstructured":"Hanamura, I. et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108, 1724\u20131732 (2006).","journal-title":"Blood"},{"key":"53_CR8","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier, S. et al. Genomic complexity of multiple myeloma and its clinical implications. Nat. Rev. Clin. Oncol. 14, 100\u2013113 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"53_CR9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2009.22.2257","volume":"28","author":"J Blad\u00e9","year":"2010","unstructured":"Blad\u00e9, J., Dimopoulos, M., Rosi\u00f1ol, L., Rajkumar, S. V. & Kyle, R. A. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. J. Clin. Oncol. 28, 690\u2013697 (2010).","journal-title":"J. Clin. Oncol."},{"key":"53_CR10","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582\u20132590 (2007).","journal-title":"N. Engl. J. Med."},{"key":"53_CR11","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113, 5412\u20135417 (2009).","journal-title":"Blood"},{"key":"53_CR12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57\u201370 (2000).","journal-title":"Cell"},{"key":"53_CR13","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00460-4","volume":"8","author":"S Tyekucheva","year":"2017","unstructured":"Tyekucheva, S. et al. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat. Commun. 8, 420 (2017).","journal-title":"Nat. Commun."},{"key":"53_CR14","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1038\/leu.2017.102","volume":"31","author":"SV Glavey","year":"2017","unstructured":"Glavey, S. V. et al. Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. Leukemia 31, 2426\u20132434 (2017).","journal-title":"Leukemia"},{"key":"53_CR15","doi-asserted-by":"crossref","first-page":"17460","DOI":"10.1073\/pnas.1206653109","volume":"109","author":"CP El-Haibi","year":"2012","unstructured":"El-Haibi, C. P. et al. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc. Natl Acad. Sci. USA 109, 17460\u201317465 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"53_CR16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1158\/2159-8290.CD-17-0284","volume":"8","author":"OMT Pearce","year":"2018","unstructured":"Pearce, O. M. T. et al. Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers. Cancer Discov. 8, 304\u2013319 (2018).","journal-title":"Cancer Discov."},{"key":"53_CR17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nm1764","volume":"14","author":"G Finak","year":"2008","unstructured":"Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518\u2013527 (2008).","journal-title":"Nat. Med."},{"key":"53_CR18","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/ng.3225","volume":"47","author":"A Calon","year":"2015","unstructured":"Calon, A. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47, 320\u2013329 (2015).","journal-title":"Nat. Genet."},{"key":"53_CR19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.euf.2017.05.013","volume":"5","author":"F Petitprez","year":"2019","unstructured":"Petitprez, F. et al. PD-L1 expression and CD8+ T-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer. Eur. Urol. Focus 5, 192\u2013196 (2019).","journal-title":"Eur. Urol. Focus"},{"key":"53_CR20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203\u2013213 (2003).","journal-title":"N. Engl. J. Med."},{"key":"53_CR21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1517\/14728222.9.2.359","volume":"9","author":"K Podar","year":"2005","unstructured":"Podar, K., Hideshima, T., Chauhan, D. & Anderson, K. C. Targeting signalling pathways for the treatment of multiple myeloma. Expert Opin. Ther. Targets 9, 359\u2013381 (2005).","journal-title":"Expert Opin. Ther. Targets"},{"key":"53_CR22","first-page":"4","volume":"32","author":"B Klein","year":"1995","unstructured":"Klein, B. Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. Semin. Hematol. 32, 4\u201319 (1995).","journal-title":"Semin. Hematol."},{"key":"53_CR23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000203610","volume":"98","author":"M Sawanobori","year":"1997","unstructured":"Sawanobori, M. et al. Natural killer cell frequency and serum cytokine levels in monoclonal gammopathies: correlation of bone marrow granular lymphocytes to prognosis. Acta Haematol. 98, 150\u2013154 (1997).","journal-title":"Acta Haematol."},{"key":"53_CR24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","volume":"98","author":"RJ Pessoa de Magalh\u00e3es","year":"2013","unstructured":"Pessoa de Magalh\u00e3es, R. J. et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 98, 79\u201386 (2013).","journal-title":"Haematologica"},{"key":"53_CR25","doi-asserted-by":"crossref","first-page":"e127807","DOI":"10.1172\/jci.insight.127807","volume":"4","author":"JK Bailur","year":"2019","unstructured":"Bailur, J. K. et al. Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight 4, e127807 (2019).","journal-title":"JCI Insight"},{"key":"53_CR26","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood-2015-01-623975","volume":"126","author":"P Leone","year":"2015","unstructured":"Leone, P. et al. Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing. Blood 126, 1443\u20131451 (2015).","journal-title":"Blood"},{"key":"53_CR27","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1172\/JCI88169","volume":"128","author":"Y Kawano","year":"2018","unstructured":"Kawano, Y. et al. Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. J. Clin. Invest. 128, 2487\u20132499 (2018).","journal-title":"J. Clin. Invest."},{"key":"53_CR28","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","volume":"23","author":"X Feng","year":"2017","unstructured":"Feng, X. et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin. Cancer Res. 23, 4290\u20134300 (2017).","journal-title":"Clin. Cancer Res."},{"key":"53_CR29","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.4049\/jimmunol.1203373","volume":"190","author":"IR Ramachandran","year":"2013","unstructured":"Ramachandran, I. R. et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J. Immunol. 190, 3815\u20133823 (2013).","journal-title":"J. Immunol."},{"key":"53_CR30","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ccell.2018.02.007","volume":"33","author":"K Nakamura","year":"2018","unstructured":"Nakamura, K. et al. Dysregulated IL-18 Is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. Cancer Cell 33, 634\u2013648.e5 (2018).","journal-title":"Cancer Cell"},{"key":"53_CR31","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","volume":"114","author":"Y Zheng","year":"2009","unstructured":"Zheng, Y. et al. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis. Blood 114, 3625\u20133628 (2009).","journal-title":"Blood"},{"key":"53_CR32","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/path.4860","volume":"241","author":"N De Beule","year":"2017","unstructured":"De Beule, N. et al. Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation. J. Pathol. 241, 534\u2013546 (2017).","journal-title":"J. Pathol."},{"key":"53_CR33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1600-0609.1990.tb00443.x","volume":"45","author":"A Osterborg","year":"1990","unstructured":"Osterborg, A., Nilsson, B., Bj\u00f6rkholm, M., Holm, G. & Mellstedt, H. Natural killer cell activity in monoclonal gammopathies: relation to disease activity. Eur. J. Haematol. 45, 153\u2013157 (1990).","journal-title":"Eur. J. Haematol."},{"key":"53_CR34","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/sj.onc.1210691","volume":"27","author":"C Scavelli","year":"2008","unstructured":"Scavelli, C. et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 27, 663\u2013674 (2008).","journal-title":"Oncogene"},{"key":"53_CR35","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2018-01-825240","volume":"132","author":"SA Minnie","year":"2018","unstructured":"Minnie, S. A. et al. Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade. Blood 132, 1675\u20131688 (2018).","journal-title":"Blood"},{"key":"53_CR36","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","volume":"111","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri, A. et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111, 785\u2013789 (2008).","journal-title":"Blood"},{"key":"53_CR37","first-page":"63","volume":"230","author":"B Perussia","year":"1998","unstructured":"Perussia, B. Fc receptors on natural killer cells. Curr. Top. Microbiol. Immunol. 230, 63\u201388 (1998).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"53_CR38","volume":"10","author":"C Yang","year":"2019","unstructured":"Yang, C. et al. Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. Nat. Commun. 10, 3931 (2019).","journal-title":"Nat. Commun."},{"key":"53_CR39","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fimmu.2013.00012","volume":"4","author":"G Bernardini","year":"2013","unstructured":"Bernardini, G., Scium\u00e8, G. & Santoni, A. Differential chemotactic receptor requirements for NK cell subset trafficking into bone marrow. Front. Immunol. 4, 12 (2013).","journal-title":"Front. Immunol."},{"key":"53_CR40","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.4049\/jimmunol.176.8.4622","volume":"176","author":"C Baecher-Allan","year":"2006","unstructured":"Baecher-Allan, C., Wolf, E. & Hafler, D. A. MHC class II expression identifies functionally distinct human regulatory T cells. J. Immunol. 176, 4622\u20134631 (2006).","journal-title":"J. Immunol."},{"key":"53_CR41","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1126\/science.1925600","volume":"254","author":"K Karalis","year":"1991","unstructured":"Karalis, K. et al. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 254, 421\u2013423 (1991).","journal-title":"Science"},{"key":"53_CR42","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1002\/eji.200526122","volume":"35","author":"K Bratke","year":"2005","unstructured":"Bratke, K., Kuepper, M., Bade, B., Virchow, J. C. Jr. & Luttmann, W. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood. Eur. J. Immunol. 35, 2608\u20132616 (2005).","journal-title":"Eur. J. Immunol."},{"key":"53_CR43","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1073\/pnas.1718217115","volume":"115","author":"E Ahn","year":"2018","unstructured":"Ahn, E. et al. Role of PD-1 during effector CD8 T cell differentiation. Proc. Natl Acad. Sci. USA 115, 4749\u20134754 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"53_CR44","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1084\/jem.20142237","volume":"212","author":"PM Odorizzi","year":"2015","unstructured":"Odorizzi, P. M., Pauken, K. E., Paley, M. A., Sharpe, A. & Wherry, E. J. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells. J. Exp. Med. 212, 1125\u20131137 (2015).","journal-title":"J. Exp. Med."},{"key":"53_CR45","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.celrep.2015.06.059","volume":"12","author":"AM Roccaro","year":"2015","unstructured":"Roccaro, A. M. et al. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Rep. 12, 622\u2013635 (2015).","journal-title":"Cell Rep."},{"key":"53_CR46","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.3109\/10428190903216804","volume":"50","author":"RD Brown","year":"2009","unstructured":"Brown, R. D. et al. Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma. Leuk. Lymphoma 50, 1860\u20131864 (2009).","journal-title":"Leuk. Lymphoma"},{"key":"53_CR47","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2141.2000.02131.x","volume":"110","author":"M Raitakari","year":"2000","unstructured":"Raitakari, M. et al. T-cell expansions in patients with multiple myeloma have a phenotype of cytotoxic T cells. Br. J. Haematol. 110, 203\u2013209 (2000).","journal-title":"Br. J. Haematol."},{"key":"53_CR48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2257.1994.tb00414.x","volume":"16","author":"A Tienhaara","year":"1994","unstructured":"Tienhaara, A. & Pelliniemi, T. T. Peripheral blood lymphocyte subsets in multiple myeloma and monoclonal gammopathy of undetermined significance. Clin. Lab. Haematol. 16, 213\u2013223 (1994).","journal-title":"Clin. Lab. Haematol."},{"key":"53_CR49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-010-0919-9","volume":"60","author":"L Wu","year":"2011","unstructured":"Wu, L. et al. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol. Immunother. 60, 61\u201373 (2011).","journal-title":"Cancer Immunol. Immunother."},{"key":"53_CR50","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12032-007-0007-y","volume":"24","author":"V Jurisic","year":"2007","unstructured":"Jurisic, V., Srdic, T., Konjevic, G., Markovic, O. & Colovic, M. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med. Oncol. 24, 312\u2013317 (2007).","journal-title":"Med. Oncol."},{"key":"53_CR51","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1158\/0008-5472.CAN-15-1320","volume":"75","author":"A Ponzetta","year":"2015","unstructured":"Ponzetta, A. et al. Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment. Cancer Res. 75, 4766\u20134777 (2015).","journal-title":"Cancer Res."},{"key":"53_CR52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13045-016-0345-3","volume":"9","author":"C Zelle-Rieser","year":"2016","unstructured":"Zelle-Rieser, C. et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J. Hematol. Oncol. 9, 116 (2016).","journal-title":"J. Hematol. Oncol."},{"key":"53_CR53","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3389\/fimmu.2018.01492","volume":"9","author":"B Castella","year":"2018","unstructured":"Castella, B., Foglietta, M., Riganti, C. & Massaia, M. V\u03b39V\u03b42 T Cells in the bone marrow of myeloma patients: a paradigm of microenvironment-induced immune suppression. Front. Immunol. 9, 1492 (2018).","journal-title":"Front. Immunol."},{"key":"53_CR54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/cei.12196","volume":"175","author":"AC Chan","year":"2014","unstructured":"Chan, A. C. et al. Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. Clin. Exp. Immunol. 175, 49\u201358 (2014).","journal-title":"Clin. Exp. Immunol."},{"key":"53_CR55","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2010.12.010","volume":"140","author":"MV Dhodapkar","year":"2011","unstructured":"Dhodapkar, M. V. & Richter, J. Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. Clin. Immunol. 140, 160\u2013166 (2011).","journal-title":"Clin. Immunol."},{"key":"53_CR56","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3389\/fonc.2018.00508","volume":"8","author":"B Castella","year":"2018","unstructured":"Castella, B., Melaccio, A., Foglietta, M., Riganti, C. & Massaia, M. V\u03b39V\u03b42 T cells as strategic weapons to improve the potency of immune checkpoint blockade and immune interventions in human myeloma. Front. Oncol. 8, 508 (2018).","journal-title":"Front. Oncol."},{"key":"53_CR57","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1158\/2326-6066.CIR-13-0129","volume":"2","author":"ML Ortiz","year":"2014","unstructured":"Ortiz, M. L., Lu, L., Ramachandran, I. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the development of lung cancer. Cancer Immunol. Res. 2, 50\u201358 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"53_CR58","doi-asserted-by":"crossref","first-page":"54173","DOI":"10.18632\/oncotarget.17013","volume":"8","author":"Z Fang","year":"2017","unstructured":"Fang, Z. et al. Myeloid-derived suppressor cell and macrophage exert distinct angiogenic and immunosuppressive effects in breast cancer. Oncotarget 8, 54173\u201354186 (2017).","journal-title":"Oncotarget"},{"key":"53_CR59","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","volume":"12","author":"DI Gabrilovich","year":"2012","unstructured":"Gabrilovich, D. I., Ostrand-Rosenberg, S. & Bronte, V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12, 253\u2013268 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"53_CR60","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423\u20131437 (2013).","journal-title":"Nat. Med."},{"key":"53_CR61","volume":"8","author":"GX Zheng","year":"2017","unstructured":"Zheng, G. X. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).","journal-title":"Nat. Commun."},{"key":"53_CR62","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-019-1836-7","volume":"20","author":"A Taylor-Weiner","year":"2019","unstructured":"Taylor-Weiner, A. et al. Scaling computational genomics to millions of individuals with GPUs. Genome Biol. 20, 228 (2019).","journal-title":"Genome Biol."},{"key":"53_CR63","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1109\/TPAMI.2012.240","volume":"35","author":"VYF Tan","year":"2013","unstructured":"Tan, V. Y. F. & F\u00e9votte, C. Automatic relevance determination in nonnegative matrix factorization with the \u03b2-divergence. IEEE Trans. Pattern Anal. Mach. Intell. 35, 1592\u20131605 (2013).","journal-title":"IEEE Trans. Pattern Anal. Mach. Intell."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-020-0053-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-020-0053-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-020-0053-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T04:39:19Z","timestamp":1670387959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-020-0053-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":63,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["53"],"URL":"https:\/\/doi.org\/10.1038\/s43018-020-0053-3","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,27]]},"assertion":[{"value":"30 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.G. receives research funds from IBM and Pharmacyclics and is an inventor on patent applications related to MuTect, ABSOLUTE, MutSig, MSMuTect and POLYSOLVER. I.M.G. has a consulting\/advisory role with GSK, AbbVie and Bristol Myers Squibb. I.M.G has a consulting role with Sanofi, Janssen Pharmaceuticals, Takeda, Celgene, Karyopharm, GNS, Cellectar Biosciences, Medscape, Genetech, Adaptive Biotechnologies, Aptitude, Curio Science, Magenta Therapeutics and Oncopeptides. I.M.G. received research funding\/ honoraria from Celgene, Takeda, Bristol Myers Squibb, Janssen Pharmaceuticals and Amgen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}